https://www.selleckchem.com/ALK.html
Locoregional therapies are downstaging methods for patients with hepatocellular carcinoma (HCC) outside Milan criteria. Sorafenib was the first systemic therapy tested in a neoadjuvant setting of liver transplantation, but with unsatisfactory results due to minimal response rate(1). Recently, immune checkpoint inhibitors have been shown to control HCC in a significant fraction of patients and to even induce complete response (2). This article is protected by copyright. All rights reserved.BACKGROUND Individuals with a high total nevus count (TNC) ar
إعجاب
علق
شارك
